Collegium Pharmaceutical Inc. has completed the acquisition of AZSTARYS from Corium Therapeutics to expand its existing portfolio of ADHD medications [1].
This expansion signals a strategic move to capture a larger share of the ADHD treatment market by adding differentiated medicines. The acquisition, combined with recent financial gains, has increased the company's visibility among investors [3].
The Stoughton, Massachusetts-based company reported a profit of $14.5 million [2] during its first quarter of 2026 [4]. This financial performance resulted in a net income of 40 cents per share [2].
Company officials said the addition of AZSTARYS is a "Highly Complementary and Differentiated Medicine with Significant Growth Potential to Collegium's Existing ADHD Portfolio" [1]. The move is intended to diversify the company's offerings and scale its reach within the specialty pharmaceutical sector [1].
During the first quarter 2026 earnings call, Ian Karp, the head of investor relations, welcomed participants to the financial review [4]. The company's current trajectory follows previous reporting periods, including a Q4 2025 reported earnings per share of $0.4273 [5].
Investors have noted the company's focus on the ADHD space as a primary driver for stock attention [3]. By integrating AZSTARYS, Collegium aims to leverage the drug's specific clinical profile to complement its current product line [1].
“Collegium Pharmaceutical Inc. reported profit of $14.5 million in its first quarter.”
The acquisition of AZSTARYS allows Collegium Pharmaceutical to diversify its ADHD product pipeline, reducing reliance on a single medication. By pairing this strategic growth with a profitable first quarter, the company is positioning itself as a consolidated player in the neuropsychiatric pharmaceutical market, which may attract further institutional investment.
